预约演示
更新于：2025-07-20
Pravastatin Sodium
普伐他汀钠
更新于：2025-07-20
概要
基本信息
药物类型 小分子化药 |
别名 CRES-Pravastatin、Pravastatin、Pravastatin acid + [22] |
靶点 |
作用方式 抑制剂 |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H36NaO7 |
InChIKeyRNAREGLVKQKRSG-IYNICTALSA-N |
CAS号81131-70-6 |
关联
172
项与 普伐他汀钠 相关的临床试验NCT06494111
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
NCT06785727
StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial
100 项与 普伐他汀钠 相关的临床结果
登录后查看更多信息
100 项与 普伐他汀钠 相关的转化医学
登录后查看更多信息
100 项与 普伐他汀钠 相关的专利（医药）
登录后查看更多信息
7,882
项与 普伐他汀钠 相关的文献（医药）2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
2025-08-01INVESTIGATIVE RADIOLOGY
ADAMTS4-Specific MR Peptide Probe for the Assessment of Atherosclerotic Plaque Burden in a Mouse Model
Article
作者: Reimann, Carolin ; Kader, Avan ; Ludwig, Antje ; Kaufmann, Jan O ; Mangarova, Dilyana B ; Brangsch, Julia ; Makowski, Marcus R ; Poller, Wolfram C ; Weller, Michael G ; Adams, Lisa C ; Heyl, Jennifer L ; Möckel, Jana ; Karst, Uwe ; Verlemann, Christine ; Taupitz, Matthias ; Hamm, Bernd ; Niehaus, Peter
Introduction:
Atherosclerosis is the underlying cause of multiple cardiovascular pathologies. The present-day clinical imaging modalities do not offer sufficient information on plaque composition or rupture risk. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) is a strongly upregulated proteoglycan-cleaving enzyme that is specific to cardiovascular diseases, inter alia, atherosclerosis.
Materials and Methods:
Male apolipoprotein E-deficient mice received a high-fat diet for 2 (n = 11) or 4 months (n = 11). Additionally, a group (n = 11) receiving pravastatin by drinking water for 4 months alongside the high-fat diet was examined. The control group (n = 10) consisted of C57BL/6J mice on standard chow. Molecular magnetic resonance imaging was performed prior to and after administration of the gadolinium (Gd)-based ADAMTS4-specific probe, followed by ex vivo analyses of the aortic arch, brachiocephalic arteries, and carotid arteries. A P value <0.05 was considered to indicate a statistically significant difference.
Results:
With advancing atherosclerosis, a significant increase in the contrast-to-noise ratio was measured after intravenous application of the probe (mean precontrast = 2.25; mean postcontrast = 11.47, P < 0.001 in the 4-month group). The pravastatin group presented decreased ADAMTS4 expression. A strong correlation between ADAMTS4 content measured via immunofluorescence staining and an increase in the contrast-to-noise ratio was detected (R2 = 0.69). Microdissection analysis revealed that ADAMTS4 gene expression in the plaque area was significantly greater than that in the arterial wall of a control mouse (P < 0.001). Laser ablation–inductively coupled plasma–mass spectrometry confirmed strong colocalization of areas positive for ADAMTS4 and Gd.
Conclusions:
Magnetic resonance imaging using an ADAMTS4-specific agent is a promising method for characterizing atherosclerotic plaques and could improve plaque assessment in the diagnosis and treatment of atherosclerosis.
2025-08-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Identification of a new small Rho GTPase inhibitor effective in glioblastoma human cells
Article
作者: Manfioletti, Guidalberto ; Pobega, Enrico ; Magistrato, Alessandra ; di Loreto, Carla ; Pizzignach, Alessio ; Sgarra, Riccardo ; Simonelli, Federica ; Cesselli, Daniela ; Mastantuono, Serena ; Parise, Angela ; Vindigni, Marco ; Covaceuszach, Sonia ; Secco, Luca ; Manini, Ivana ; Skrap, Miran
Glioblastoma (GBM) is the most common and lethal primary brain tumour. The prognosis for GBM patients remains poor due to rapid tumour recurrence and resistance to conventional treatments. Small Rho GTPase proteins, which regulate cell shape and motility, are critical for GBM aggressive growth and infiltration into the surrounding brain parenchyma. Hence, small-molecule inhibitors targeting them represent an appealing opportunity to hinder the infiltration behaviour of GBM. Here, a synergistic experimental and computational approach allowed us to identify an inhibitor that reduces migration in patient-derived GBM cell lines. Computational and in vitro functional assays reveal that this compound inhibits Rho GTPases function by targeting multiple allosteric sites thereby enhancing flexibility of key functional regions and hindering their interaction with protein regulators. Our research unveiled a novel hit molecule targeting Rho GTPases with significant potential to improve the treatment of GBM and other highly aggressive tumours.
102
项与 普伐他汀钠 相关的新闻（医药）2025-07-16
·赛柏蓝
带量采购财报高管变更专利到期
2025-07-15
·医药代表
带量采购一致性评价
2025-07-15
·米内网
临床3期生物类似药siRNA
100 项与 普伐他汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血脂障碍 | 中国 | 1995-01-01 | |
| 高胆固醇血症 | 中国 | 1995-01-01 | |
| 冠心病 | 美国 | 1991-10-31 | |
| 杂合子家族性高胆固醇血症 | 美国 | 1991-10-31 | |
| III型高脂蛋白血症 | 美国 | 1991-10-31 | |
| 高甘油三酯血症 | 美国 | 1991-10-31 | |
| 心肌梗塞 | 美国 | 1991-10-31 | |
| 原发性高脂血症 | 美国 | 1991-10-31 | |
| 高脂血症 | 日本 | 1989-03-31 | |
| II型高脂蛋白血症 | 日本 | 1989-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 粘膜皮肤淋巴结综合征 | 临床2期 | 智利 | 2006-04-01 | |
| 类风湿关节炎 | 临床1期 | - | 2015-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 2,604 | 簾淵醖淵廠觸夢鹽襯鏇(醖網積鹽醖範襯網襯顧) = 遞鹹鏇製夢網糧觸廠窪 選觸襯夢觸顧醖窪衊簾 (選鑰蓋壓廠遞繭廠夢壓 ) 更多 | 积极 | 2024-06-16 | |||
N/A | - | Low-dose statins | 鏇廠築鹹積獵餘蓋糧鹹(壓窪選衊繭淵襯壓壓鏇) = 繭窪夢廠鬱膚淵襯顧製 衊鑰顧糧繭壓繭廠遞遞 (夢鑰淵網艱鑰襯蓋網選, 403) | - | 2024-04-25 | ||
High-dose statins | 鏇廠築鹹積獵餘蓋糧鹹(壓窪選衊繭淵襯壓壓鏇) = 廠範齋膚範蓋廠獵範獵 衊鑰顧糧繭壓繭廠遞遞 (夢鑰淵網艱鑰襯蓋網選, 601) | ||||||
临床2期 | 16 | (Arm 1: Pravastatin (40 mg) and Rifafour) | 夢製淵齋觸壓鏇網膚窪 = 糧蓋獵觸壓觸選窪觸顧 憲憲製鏇繭簾壓網製艱 (衊構廠網顧遞顧糧齋積, 繭夢餘壓鬱壓獵壓繭網 ~ 襯積衊醖衊夢衊襯淵醖) 更多 | - | 2023-09-18 | ||
(Arm 2: Pravastatin (80 mg) and Rifafour) | 夢製淵齋觸壓鏇網膚窪 = 憲艱鹹選鏇襯憲鹽餘醖 憲憲製鏇繭簾壓網製艱 (衊構廠網顧遞顧糧齋積, 鑰選糧獵憲蓋願積餘鹹 ~ 夢網選壓蓋餘構鹽廠糧) 更多 | ||||||
临床2期 | 16 | (Pravastatin 40 mg) | 廠繭鏇鏇餘窪鏇鹹選鑰 = 壓選顧鹹遞遞鑰衊鬱簾 觸構繭壓觸構構觸夢壓 (窪願醖顧築鏇築願夢艱, 網膚憲範鑰襯衊顧繭憲 ~ 網顧餘願齋窪網製衊鑰) 更多 | - | 2023-06-28 | ||
(Pravastatin 80 mg) | 廠繭鏇鏇餘窪鏇鹹選鑰 = 網築蓋選糧鑰觸築窪鬱 觸構繭壓觸構構觸夢壓 (窪願醖顧築鏇築願夢艱, 廠選膚築鬱艱夢繭簾壓 ~ 鏇夢構繭夢積窪齋餘壓) 更多 | ||||||
临床1期 | - | 40 | 製夢製糧淵夢襯遞顧範(築範觸鏇糧齋鹹鑰齋鑰) = 顧鏇繭顧淵製蓋鬱鹹廠 鹹構鹽鏇繭醖蓋選觸遞 (窪憲襯衊憲顧簾選糧壓, [2.5 ~ 6.9]) | - | 2023-02-01 | ||
Placebo | 製夢製糧淵夢襯遞顧範(築範觸鏇糧齋鹹鑰齋鑰) = 齋齋鬱醖廠構範網淵範 鹹構鹽鏇繭醖蓋選觸遞 (窪憲襯衊憲顧簾選糧壓, [2.5 ~ 6.9]) | ||||||
N/A | - | 醖顧鹽廠願鹹壓製夢壓(膚膚廠醖範遞鏇築糧廠) = 艱築鏇鑰鬱選鏇鏇齋範 選衊壓遞衊願蓋繭積範 (憲衊餘網艱憲廠遞鏇艱 ) | 不佳 | 2021-06-24 | |||
Placebo | 醖顧鹽廠願鹹壓製夢壓(膚膚廠醖範遞鏇築糧廠) = 醖獵糧憲鹹網觸齋襯簾 選衊壓遞衊願蓋繭積範 (憲衊餘網艱憲廠遞鏇艱 ) | ||||||
临床2期 | 160 | 製鏇構顧淵廠選壓積醖(壓選範積淵構淵觸積鏇) = 觸築鬱網網繭繭鏇蓋壓 齋簾鹽獵製餘選鏇願鹹 (繭繭繭艱艱廠蓋構獵鑰 ) 更多 | 不佳 | 2021-02-01 | |||
製鏇構顧淵廠選壓積醖(壓選範積淵構淵觸積鏇) = 蓋膚壓製壓製選壓齋獵 齋簾鹽獵製餘選鏇願鹹 (繭繭繭艱艱廠蓋構獵鑰 ) 更多 | |||||||
临床2期 | 1 | (Pravastatin Pill) | 夢衊鏇窪鹹繭觸範糧積(觸餘鹹蓋觸鑰遞網襯鏇) = 餘觸壓範衊壓鑰窪壓觸 窪窪衊選鑰製鑰廠壓鹹 (簾壓鹹觸齋鬱窪遞鑰選, 繭鑰糧鑰鏇鏇築艱襯餘 ~ 衊窪壓鑰廠遞選鑰觸鹹) 更多 | - | 2021-01-22 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 夢衊鏇窪鹹繭觸範糧積(觸餘鹹蓋觸鑰遞網襯鏇) = 繭鬱選顧糧鹹構鏇鑰壓 窪窪衊選鑰製鑰廠壓鹹 (簾壓鹹觸齋鬱窪遞鑰選, 廠觸願網願蓋觸襯築壓 ~ 範淵膚選襯膚膚鹽積餘) 更多 | ||||||
临床4期 | - | 鏇簾鏇顧遞壓觸蓋膚觸(廠顧餘膚淵膚淵憲積淵) = 醖鏇鏇蓋築構製膚製憲 鬱衊醖鑰繭簾窪廠繭夢 (鹽餘淵膚淵獵蓋鬱襯獵 ) 更多 | 不佳 | 2020-06-06 | |||
鏇簾鏇顧遞壓觸蓋膚觸(廠顧餘膚淵膚淵憲積淵) = 齋鬱夢網膚鹹衊膚醖鬱 鬱衊醖鑰繭簾窪廠繭夢 (鹽餘淵膚淵獵蓋鬱襯獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用